Data from first adult patient dosed in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated with no treatment-emergent serious adverse events (SAEs) as of six-week assessment and improvement in ...
REVEAL Phase 1/2 Adolescent and Adult Trial (Canada and U.S.): a first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA ...
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly earnings call following Independent Data Monitoring ...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett ...
Health Canada authorized the Company’s protocol amendment that expands eligibility to include patients aged 12 and older with stage four Rett syndrome in the REVEAL Phase 1/2 adult trial in Canada ...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal ...
New York News on MSN
Producer Washington Calvache Durand raises awareness for Rett syndrome with powerful short film 'Voices of Rett'
Rett syndrome, a rare and severe neurodevelopmental disorder, affects approximately 1 in 10,000 to 1 in 15,000 live bi ...
MONEY AND AWARENESS. CONCORD HIGH SCHOOL STUDENT IZZY BOOM IS BUSY WITH HER FRIENDS EMMA AND SAMMY. OH YEAH, I THINK THIS ONE’S MY FAVORITE DECORATING DUCKS. OH, THAT’S A CUTE ONE. TWO, TWO DUCK. BUT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results